Matt Zuga - 30 Jun 2021 Form 3 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Chief Financial Officer
Signature
/s/ Katherine Denby, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
30 Jun 2021
Transactions value $
$0
Form type
3
Filing time
30 Jun 2021, 18:52:05 UTC
Next filing
08 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABOS Series A-1 Preferred Stock 30 Jun 2021 Common Stock 15.7K Direct F1
holding ABOS Series B Preferred Stock 30 Jun 2021 Common Stock 10.5K Direct F1
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 46.4K $0.75 Direct F2
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 451K $1.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock have no expiration date.
F2 The shares underlying the option vest and become exercisable in 36 equal monthly installments beginning on July 29, 2019, such that the option shall be fully vested on July 29, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date.
F3 25% of the shares underlying the option shall vest and become exercisable on January 1, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney No Table I securities beneficially owned